FDA finalizes PFDD Guidance 3 on selecting fit-for-purpose clinical outcome assessments 

The US Food and Drug Administration (FDA) has released the third guidance in its Patient-Focused Drug Development (PFDD) series, outlining how to select, develop, or modify clinical outcome assessments (COAs) that are fit-for-purpose in medical product development and regulatory decision-making. The FDA noted it is posting the document “to provide advance notice to the public,” with a Federal Register notice to follow after the lapse in appropriations ends. 

The final guidance, “Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments,” completes “the third in a series of four methodological patient-focused drug development (PFDD) guidance documents that describe how stakeholders (patients, caregivers, researchers, medical product developers, and others) can collect and submit patient experience data and other relevant information… to be used for medical product development and regulatory decision-making.” The document finalizes the draft issued on June 30, 2022. 

The guidance applies to four types of COAs: patient-reported (PRO), observer-reported (ObsRO), clinician-reported (ClinRO), and performance outcomes (PerfO), and emphasizes aligning what is measured with how it is used. It introduces a framework linking the meaningful aspect of health (MAH), concept of interest (COI), and context of use (COU), explaining that “clinical benefit is defined as ‘a positive effect on how an individual feels, functions, or survives’.” FDA also distinguishes between an instrument and its outputs, stating, “This guidance distinguishes an endpoint from the COA, and the score produced by that COA.” 

According to FDA, a COA is fit-for-purpose when “the level of validation associated with a medical product development tool is sufficient to support its context of use.” Sponsors are encouraged to provide a clear, evidence-based rationale demonstrating that chosen COAs measure outcomes meaningful to patients and can reliably support endpoint construction. 

A key feature of the document is the “Roadmap to patient-focused outcome measurement,” which guides sponsors in determining whether to use existing measures, modify them, or develop new ones. It emphasizes early engagement with FDA, patients, and subject-matter experts to ensure the selected COAs are appropriate for their intended context. The guidance also highlights the importance of accessibility, pediatric inclusion, and validation prior to pivotal trials. 

FDA outlines when each COA type is most suitable and advises that “another type of measure—a proxy-reported outcome measure—is discouraged by FDA.” It further clarifies that when COAs are administered electronically, the source of measurement remains the patient, observer, or clinician. However, if data originate directly from digital health technologies, stakeholders should refer to FDA’s separate guidance on digital tools. 

The document also focuses on ensuring score accuracy and interpretability through clear scoring rules, consistent administration, and assessment of reliability and validity. Sponsors should confirm that “scores from the COA are not overly influenced by processes/concepts that are not part of the COI” and that respondents “understand the instructions and items/tasks of the measure as intended by the measure developer.” 

Findings from validated COAs may support product labeling “if the claim is consistent with the findings and the COA’s documented measurement capabilities.” Overall, Guidance 3 aims to ensure that patient-relevant outcomes are measured using scientifically sound, interpretable, and fit-for-purpose tools that can meaningfully inform regulatory and clinical decisions.